世界中医药

目的：观察中成药养心氏片联合西药比索洛尔治疗冠心病心力衰竭的临床疗效。方法：选取2018年9月至2019年9月广西国际壮医医院收治的冠心病心力衰竭患者120例作为研究对象，按照随机数字表法分为观察组与对照组，每组60例。对照组（比索洛尔组）采用单一西药治疗，观察组（比索洛尔片+养心氏片）在对照组基础上采用养心氏片联合治疗，比较2组患者临床疗效、治疗前、后心力衰竭分级、6 min步行距离、心功能指标以及血清NT-ProBNP、 hs-CRP水平。结果：观察组的临床疗效明显好于对照组（P<0.05）；与治疗前比较，治疗后2组心力衰竭分级、6 min步行距离、治疗后2组的LVEDV、LVESV和LVEF与治疗前比较，差异均具有统计学意义（P<0.05）；且观察组LVEDV和LVESV均明显小于对照组（P<0.05)，LVEF明显高于对照组（P<0.05)；治疗后，2组血清N-末端脑钠肽前体（NT-proBNP）、高敏C反应蛋白（hs-CRP）水平均显著降低，同组治疗前后比较，差异有统计学意义（P<0.05）；治疗后，观察组血清NT-proBNP、 hs-CRP水平均显著低于对照组，2组比较差异有统计学意义（P<0.05）。结论：冠心病心力衰竭应用中成药养心氏片联合比索洛尔治疗效果明显，可有效改善患者心功能情况，值得临床广泛推广。

English Summary:

To observe the clinical effects of Chinese patent medicine Yangxinshi Tablets combined with western medicine bisoprolol in the treatment of coronary heart disease and heart failure.Methods:A total of 120 patients with coronary heart failure from September 2018 to September 2019 in Guangxi International Zhuang Medical Hospital were randomly divided into a control group(n=60)and an observation group(n=60).The control group(bisoprolol group)was treated with single western medicine, and the observation group(bisoprolol tablet Yangxinshi Tablets)was treated with Yangxinshi Tablets combined with Yangxinshi Tablets on the basis of the control group.The clinical efficacy, grade of heart failure before and after treatment, 6 min walking distance, cardiac function index and serum NT-ProBNP, hs-CRP levels were compared between the 2 groups.Results:The clinical efficacy of the observation group was significantly better than that of the control group(P<0.05).Compared with before treatment, there was statistically significant difference in the grade of heart failure, 6 min walking distance, LVEDV, LVESV and LVEF of the 2 groups after treatment(P<0.05).The LVEDV and LVESV of the observation group were significantly lower than those of the control group(P<0.05), and LVEF was significantly higher than the control group(P<0.05).After treatment, serum N-terminal brain natriuretic peptide precursor(NT-proBNP)and high sensitivity C reactive protein(hs-CRP)levels of the 2 groups were significantly decreased after treatment, and there was significant difference for the same group when compare before and after treatment(P<0.05).After treatment, the serum NT-proBNP, hs-CRP levels in the observation group were significantly lower than those in the control group after treatment, and there was significant difference between the 2 groups(P<0.05).Conclusion:The effect of Yangxinshi Tablets combined with bisoprolol in the treatment of coronary heart failure is obvious, which can effectively improve the cardiac function of patients, and is worthy of extensive clinical promotion.

查看全文查看/发表评论下载PDF阅读器